NCT01772797
Who may be able to join
Who might be able to join this trial:
- You have advanced or spreading non-small cell lung cancer (NSCLC) that got worse during or after treatment with a specific type of targeted therapy called an ALK inhibitor
- Your tumor has been tested and shows a specific genetic change (called an ALK rearrangement) in 15% or more of the tumor cells, measured by a test called FISH
- Your disease can be tracked and measured using standard imaging scans (confirm with trial site)
Who may not be able to join:
- You have cancer that has spread to the brain and is causing symptoms, or requires increasing doses of steroids or other brain-focused treatments to keep it under control
- You have a history of serious scarring or inflammation of the lung tissue, including significant lung damage from previous radiation treatment
- You have significant heart problems (confirm with trial site)
- Your liver, kidneys, or other organs are not working well enough, based on blood test results (confirm with trial site)
- You are taking certain medications that strongly affect how the body processes drugs, and you cannot stop taking them at least one week before starting the trial
- You are taking certain other medications that are broken down by the same pathways in the body, and you cannot stop them at least one week before starting the trial (confirm with trial site)
- You have significant, uncontrolled digestive system problems or disease affecting your stomach or intestines
- You have previously been treated with a type of drug called an HSP90 inhibitor
- You received radiation treatment to the lung within 4 weeks before starting the trial, or you have not yet recovered from side effects of previous radiation therapy
- You are currently pregnant or breastfeeding
- You have a history of pancreatitis (inflammation of the pancreas), or have had abnormal blood levels of certain digestive enzymes (amylase or lipase) due to a pancreas condition
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Incidence rate of Dose Limiting Toxicities (DLT)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.